ArticleJournal of pharmacokinetics and pharmacodynamics2005
Population cell life span models for effects of drugs following indirect mechanisms of action.
Article in Journal of pharmacokinetics and pharmacodynamics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.Journal of clinical pharmacology · 2012Trial
- Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects.Clinical pharmacokinetics · 2009Trial
- Delay differential equations based models in NONMEM.Journal of pharmacokinetics and pharmacodynamics · 2021Article
- CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis.British journal of clinical pharmacology · 2019Observational
- A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.CPT: pharmacometrics & systems pharmacology · 2015Article
- Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.Journal of pharmacokinetics and pharmacodynamics · 2014Article
- Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Clinical pharmacokinetics · 2013Review
- The Validation of a New Visual Anaemia Evaluation Tool HemoHue HH1 in Patients with End-Stage Renal Disease.Anemia · 2013Article
- Modeling of red blood cell life-spans in hematologically normal populations.Journal of pharmacokinetics and pharmacodynamics · 2012Article
- Lifespan based indirect response models.Journal of pharmacokinetics and pharmacodynamics · 2012Review
- Multi-response model for rheumatoid arthritis based on delay differential equations in collagen-induced arthritic mice treated with an anti-GM-CSF antibody.Journal of pharmacokinetics and pharmacodynamics · 2012Article
- Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.The AAPS journal · 2011Article
- Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.Journal of pharmacokinetics and pharmacodynamics · 2008Article
- Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects.Clinical pharmacokinetics · 2008Article
- Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.Journal of pharmacokinetics and pharmacodynamics · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pharmacokinetic/pharmacodynamic (PK/PD) models for hematological drug effects exist that assume that cells are produced by a zero- or first-order process, survive for a specific duration (cell lifespan), and then are lost. Due to the fact that delay differential equations (DDE) are needed for cell lifespan models, their software implementation is not straightforward. Our objective is to demonstrate methods to implement three different cell lifespan models for dealing with hematological drug effects and to evaluate the performance of NONMEM to estimate the model parameters. For the basic lifespan indirect response (LIDR) model, cells are produced by a zero-order process and removed due to senescence. The modified LIDR model adds a precursor pool. The LIDR model of cytotoxicity assumes a three-pool indirect model to account for the cell proliferation with capacity-limited cytotoxicity followed by maturation, and removal from the circulation. A numerical method (method of steps) implementing DDE in NONMEM was introduced. Simulation followed by estimation was used to evaluate NONMEM performance and the impact of the minimization algorithm (first-order method vs. first-order conditional estimation method) and the model for residual variability on the estimates of the population parameters. The FOCE method combined with log-transformation of data was found to be superior. This report provides methodology that will assist in application of population methods for assessing hematological responses to various types of drugs.
Indexed as
Identifiers
16328102What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.